STAT

Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...
blockchain

MIT Recursive LLMs vs Standard LLMs: Latest Analysis on How Self-Calling Models Improve ...

According to @_avichawla on Twitter, MIT researchers detail Recursive LLMs that call themselves to decompose tasks, verify intermediate steps, and iterate until convergence; as reported by MIT CSAIL ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Reuters

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
The Motley Fool

Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Shares

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...
The Motley Fool

Is Recursion Pharmaceuticals a Millionaire Maker?

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...